Twisted light carrying orbital angular momentum (OAM), which featuring helical phase front, has shown its potential applications in diverse areas, especially in optical communications in free space and specially designed fibers, e.g. a vortex fiber. Instead of specially designed fibers extensively used in the reported OAM-based fiber transmission experiments, here we demonstrate the viability of a conventional graded-index multi-mode fiber (MMF) for OAM multiplexing transmission with less digital signal processing (DSP) complexity. We demonstrate a 120-Gbit/s quadrature phase-shift keying (QPSK) signal transmission in an 8.8-km OM4 MMF by using OAM mode multiplexing with all the modes in the first two mode-groups (OAM01L, OAM01R, OAM+11L, OAM+11R, OAM-11L, OAM-11R) with only 2×2 and 4×4 multiple-input-multiple-output (MIMO) equalization. Moreover, we demonstrate the data-carrying two OAM mode groups multiplexing transmission over the 8.8-km MMF without MIMO equalization. These demonstrations may open up new perspectives to enable the realistic use of OAM-based MMF solution in data centers and super-computers.

2014-01-01·BioMed Research International3区 · 生物学

Dissolution of Arsenic Minerals Mediated by Dissimilatory Arsenate Reducing Bacteria: Estimation of the Physiological Potential for Arsenic Mobilization

3区 · 生物学

ArticleOA

作者: Aleksandra, Sklodowska ; Aleksandra, Mantur ; Lukasz, Drewniak ; Liwia, Rajpert

The aim of this study was characterization of the isolated dissimilatory arsenate reducing bacteria in the context of their potential for arsenic removal from primary arsenic minerals through reductive dissolution. Four strains,Shewanellasp. OM1,Pseudomonassp. OM2,Aeromonassp. OM4, andSerratiasp. OM17, capable of anaerobic growth with As (V) reduction, were isolated from microbial mats from an ancient gold mine. All of the isolated strains: (i) produced siderophores that promote dissolution of minerals, (ii) were resistant to dissolved arsenic compounds, (iii) were able to use the dissolved arsenates as the terminal electron acceptor, and (iii) were able to use copper minerals containing arsenic minerals (e.g., enargite) as a respiratory substrate. Based on the results obtained in this study, we postulate that arsenic can be released from some As-bearing polymetallic minerals (such as copper ore concentrates or middlings) under reductive conditions by dissimilatory arsenate reducers in indirect processes.

2007-05-01·Arteriosclerosis, Thrombosis, and Vascular Biology1区 · 医学

The Fab Fragment of a Novel Anti-GPVI Monoclonal Antibody, OM4, Reduces In Vivo Thrombosis Without Bleeding Risk in Rats

1区 · 医学

Article

作者: Matsumoto, Yutaka ; Tandon, Narendra N. ; Li, Haiquan ; Liu, Yongge ; Guertin, Moe ; Kambayashi, Junichi ; Concepcion, Alice ; Takizawa, Hisao ; Gong, Xiaoqi ; Lockyer, Simon

Background— Inhibition of GPVI has been proposed as a useful antithrombotic strategy; however, in vivo proof-of-concept animal studies targeting GPVI are lacking. We evaluated a novel anti-human GPVI monoclonal antibody OM4 Fab in rats. Methods and Results— OM4 Fab specifically inhibited collagen-induced aggregation of rat platelets in vitro with an IC 50 of 20 to 30 μg/mL but not ADP and AA-induced platelet aggregation. After intravenous administration of OM4 Fab, a rapid inhibition of ex vivo platelet aggregation was observed with a gradual recovery within 60 to 90 minutes which corresponded to the decline in OM4 Fab plasma concentration and time-dependent decrease in platelet-bound OM4 Fab. In contrast to previous reports in mice, intravenous OM4 Fab did not deplete platelet GPVI. Injection of OM4 IgG caused acute thrombocytopenia. In a modified Folts model of cyclic flow reduction in rat carotid artery, the number of complete occlusions was significantly reduced by intravenous administration of OM4 Fab (20 mg/kg) before or after mechanical injury to the vessel, without prolongation of bleeding time. Conclusion— Fab fragment of the monoclonal antibody OM4 effectively inhibits collagen induced platelet aggregation in vitro and ex vivo, and in vivo thrombosis in rats without prolonging bleeding time. Antibodies against GPVI may have therapeutic potential, inhibiting thrombosis without prolonging bleeding time.

100 项与 OM4 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性髓性白血病	药物发现	美国	Oncomyx Therapeutics, Inc.	2022-03-17
头颈部肿瘤	药物发现	美国	Oncomyx Therapeutics, Inc.	2022-03-17
肺癌	药物发现	美国	Oncomyx Therapeutics, Inc.	2022-03-17
淋巴瘤	药物发现	美国	Oncomyx Therapeutics, Inc.	2022-03-17